Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) and may include paid advertising.

• LaFleur Minerals anticipates the imminent completion of its Preliminary Economic Assessment (“PEA”) to guide its pending gold production at a sprawling site in the renowned Abitibi Greenstone Belt of Eastern Canada
• LaFleur is completing upgrades and refurbishments to get its Beacon Gold Mill operating in the next quarter with feedstock from its nearby Swanson Gold Deposit and potentially other area miners
• The company has 445 mineral claims and one mining lease at the Swanson Gold Project spanning more than 18,000 hectares (about 44,500 acres), hosting multiple gold targets, primarily the key Swanson Gold Deposit
• Company CEO Paul Ténière recently participated in a webinar that addressed the company’s assets, the company’s progress toward production, and its strategic aims

Gold explorer and near-term gold producer LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) is preparing the restart of gold production at its Beacon Gold Mill as a processing outlet for company feedstock sourced from its nearby Swanson Gold Deposit in the celebrated Abitibi Gold Belt of Eastern Canada, where more than 300 million ounces of gold have been produced historically or accounted for with current reserve estimates (https://ibn.fm/RZlLz).

“(The mill) has a name plate of 750 (tonnes per day of production capacity), but we are looking at upgrades and refinements to get that to at least 1,000 tonnes or more per day,” LaFleur CEO Paul Ténière said during a Feb. 10 webinar broadcast by Red Cloud Securities (https://ibn.fm/t5FLD). “It is able to process gold, silver, and even a little bit of base metals as well, so it can handle multi-element-type deposits. We’re fully permitted at the mill but also at the tailings storage facility for up to 1.8 million tonnes of tailings.”

LaFleur obtained the idled gold mill at a bargain price in bankruptcy proceedings a few years ago, and the mill has become a key asset thanks in part to its access to power structure and skilled labor in the heavily explored and prolific gold belt.

“The mill’s barely run since it was opened, so I would say there’s at least over 90% of capacity still left,” Ténière said. “And at the current rate that we’re looking at, we’re looking at about nine years of life for that tailings storage facility. So all of that has been kept up since we took over the asset.”

The company aims to run a 100,000-tonne bulk sample from the Swanson Gold Deposit and then build into a larger operation, and is awaiting a Preliminary Economic Assessment (“PEA”) that will provide further guidance on its plans.

“I was hoping that they (the PEA results) would be out by the time of having this discussion, but shortly they will be coming out and then we’ll be able to get a lot more detail into the economics and also the mine plan,” Ténière said.

Plans to add a dedicated rail spur through the Swanson Property and the Beacon Gold Mill site to facilitate efficient loading and transport of material would provide the company with a significant economic benefit through reduced hauling costs, decreased pollutants and increased safety by reducing truck traffic through nearby villages if such an agreement with government and railway officials can be successfully reached.

LaFleur has built its available capital through $7.8 million in financing to restart gold production at the mill (https://ibn.fm/YhlEG), which comes at a strategic inflection point as the company shifts from being primarily an explorer toward gold production and revenue generation. This transition is typically one of the hardest and most capital-intensive phases for a junior mining company and having secured sufficient funding at this moment is crucial for moving from planning into actual operations, and it seems that LaFleur has done this seamlessly. The LIFE and flow-through offerings were upsized and oversubscribed showing strong investor interest and confidence in LaFleur’s plans and assets, and funds the restart of a fully permitted mill and materially reduces execution risk at a pivotal stage in its development.

“Primarily we’re looking at Beacon to process ore from our own deposits, and we’re also looking to generate cash as quickly as possible after we’ve completed the upgrades and refurbishments,” Ténière said. “Initially we’re looking a bulk sample of 100,000 tonnes — could get up to about 4,200 ounces of gold out of that, and could be even more depending on our cutoff. But we are looking to have that going fairly quickly. Because Swanson sits on a mining lease, there’s a lot less permitting required.”

For more information, visit the company’s website at LaFleurMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to LFLRF are available in the company’s newsroom at https://ibn.fm/LFLRF

Qualified Person Statement:

All scientific and technical information contained in this article has been reviewed and approved by Louis Martin, P.Geo. (OGQ), Exploration Manager and Technical Advisor of the company and considered a Qualified Person for the purposes of NI 43-101.

• WLDS recently announced a strategic partnership with Rokid to enable neural, touch-free control for AI and AR smart glasses
• Wearable Devices Ltd. Operates at the nexus of artificial intelligence, neural sensing, and intuitive human-computer interaction
• These updates highlight the company’s broader mission: to redefine the way users interact with AI-powered wearables via natural, frictionless neural input

Wearable Devices (NASDAQ: WLDS) continues to venture into new frontiers with its proprietary neural interface technology, strategically targeting the quickly evolving smart glass and augmented reality market. In a recent announcement, the company made public its collaboration with Rokid, a leading force in human-computer interaction and AR glasses, to deliver seamless, wrist-based gesture control for Rokid’s AI and AR eyewear (ibn.fm/2mobH).

Under the partnership, WLDS’s Mudra Link neural wristband can now work with Rokid Glasses, enabling pre-mapped gestures, out-of-the-box pairing, and a seamless onboarding experience. Both companies plan to implement a joint marketing approach, as well as a consumer bundle rollout, in the second quarter of 2026.

With AI-powered smart glasses gaining wider acceptance, input remains one of the difficulties faced by the category. Although software and hardware capabilities like navigation, real-time translation, and transcription have evolved quickly, intuitive control is still not catching up quickly enough. Wearable devices are trying to solve the challenge by transforming subtle neural signals from the wrist into reliable, touch-free commands, making it possible for users to interact naturally without using touchpads, external controllers, or voice prompts.

The company already carries a solid reputation as a force in the AI-enabled wearables sector through its Mudra Link and Mudra Band products. These products enable gesture-based interaction across a broad range of platforms such as smartwatches, smartphones, VR headsets, AR glasses and other Bluetooth-enabled devices. The partnership with Rokid underscores the scalability of Wearable Devices’ technology, placing it as a foundational input layer for the entire wearable solutions ecosystem.

This strategic direction is further validated by recent moves from leading global technology companies, including Apple’s acquisition of Q.ai for approximately $2 billion. The transaction highlights a growing industry focus on the interface and input layer as the next major battleground for AI-driven devices. As artificial intelligence becomes increasingly embedded in wearables, spatial computing platforms, and ambient systems, the ability to capture user intent through natural, frictionless input is emerging as a key differentiator. Apple’s investment in silent and micro-expression-based interaction reinforces the view that future AI value creation will extend beyond software models to the foundational technologies that enable intuitive, hands-free, and context-aware user interaction, directly aligning with the long-term direction of advanced wearable ecosystems.

Looking ahead to 2026, the company intends to build on this momentum and redefine the boundaries of human-machine interaction through its emerging AI initiatives. Beyond gesture recognition, the company is advancing its proprietary Large MUAP Model (“LMM”) and edge AI capabilities with the goal of supporting a new neural standard for the AI era. The company’s technology is designed to embrace the latest AI innovations, introducing” Vibe Coding” tools accessible to developers, alongside autonomous agent-based workflows utilized by the company to accelerate further development. By processing intent directly on the wrist, the company aims to ensure that as digital systems become smarter, user control remains seamless and intuitive.

These latest updates highlight Wearable Devices’ broader mission: to redefine human-computer interaction by making control intuitive, effortless and invisible. From neural interfaces that adapt to individual users to gesture based inputs for AI glasses, WLDS is creating the needed framework that makes it possible for intelligent devices to be used in everyday life.

For more information, visit www.WearableDevices.co.il.

NOTE TO INVESTORS: The latest news and updates relating to WLDS are available in the company’s newsroom at https://ibn.fm/WLDS

• LIXTE recently announced advances in its approach to cancer therapy through its proprietary compound LB-100
• Alongside clinical development news, LIXTE is sponsoring the Good Health: Mind, Body & Soul Summit
• These two announcements paint a picture of a company advancing on multiple fronts

LIXTE Biotechnology Holdings (NASDAQ: LIXT) is entering 2026 with momentum on both scientific and community fronts, announcing progress in its lead oncology program while also sponsoring a major health and wellness summit focused on addressing disparities in care. The company’s announcements highlight advances surrounding LB-100, its first-in-class cancer therapy candidate designed to enhance the effectiveness of existing treatments and underscore its involvement in community health initiatives through its sponsorship of the Good Health: Mind, Body & Soul Summit.

Last week, LIXTE outlined advances in its approach to cancer therapy through its proprietary compound LB-100, which works by inhibiting Protein Phosphatase 2a (“PP2A”), an enzyme involved in cell growth regulation, DNA repair and immune modulation. The company described this mechanism as a “novel approach to enhancing cancer therapy,” positioning LB-100 as a potential amplifier of existing chemotherapies and immunotherapies rather than a standalone agent.

The release explains that, by targeting PP2A, LB-100 may make tumor cells more susceptible to treatment, promoting stronger immune responses and enhancing the effects of existing therapies. This strategy reflects a broader trend in oncology to improve outcomes by augmenting established treatment regimens rather than relying solely on new cytotoxic agents. LB-100 has shown evidence of tolerability and anticancer activity in early clinical settings, and LIXTE continues to pursue clinical evaluation in multiple tumor types.

Clinical programs for LB-100 have drawn attention because they explore its use not only in combination with traditional chemotherapies but also alongside modern immunotherapies, which are transforming cancer care for many patients. The company’s emphasis on PP2A inhibition aligns with its broader oncology strategy, which has been documented in other industry and investor resources as a unique therapeutic approach within precision oncology.

Alongside clinical development news, LIXTE announced that it is sponsoring the Good Health: Mind, Body & Soul Summit, an invitation-only event scheduled for February 19 at Morehouse College in Atlanta. The summit, rooted in the legacy and music of hip-hop group De La Soul, is designed to explore health-equity issues impacting Black men and their families, bringing together leaders in health, culture, science and community to discuss a wide range of topics including cancer, heart disease, mental health and overall wellness.

According to the company, the summit aligns with LIXTE’s mission as a clinical-stage pharmaceutical company advancing cancer care through LB-100, as well as the work of its European subsidiary LIORA Technologies. The company’s sponsorship underlines its recognition that scientific progress must be paired with community engagement and awareness, particularly for populations that historically experience health disparities.

The Good Health summit will feature discussions on disease prevention, treatment access, mental well-being and generational health themes, aiming to foster a space where medical science and lived experience intersects. By participating in such initiatives, LIXTE is extending its influence beyond drug development into conversations about how healthcare systems and scientific innovation can better serve underrepresented communities. This integration of clinical ambition with social advocacy reflects a broader trend among biotechnology firms to address both scientific and societal dimensions of illness and treatment.

Taken together, these two announcements paint a picture of a company advancing on multiple fronts. On the scientific side, LIXTE’s work with LB-100 represents an innovative angle in oncology drug development, not by creating yet another cytotoxic agent but by enhancing the performance of existing therapies and potentially increasing their effectiveness. This approach may appeal to clinicians and researchers looking for ways to improve outcomes for patients with resistant or hard-to-treat cancers.

On the community engagement side, sponsoring the Good Health Summit positions LIXTE as an organization aware of the broader context in which cancer care and general health services are delivered. By aligning its corporate mission with an event focused on health equity, the company is helping draw attention to disparities that impact access, outcomes and public understanding of disease. This reflects an understanding within the broader pharmaceutical industry that scientific innovation and community engagement are mutually reinforcing aspects of long-term success.

Looking ahead, developments such as advances in LB-100’s clinical programs and participation in community health initiatives could help LIXTE shape its identity not just as a biotech developing a promising oncology compound but as a company engaged in the broader dialogue of health equity. For investors, clinicians and patients alike, these dual narratives of scientific progress and social engagement may help position LIXTE as a company aware of both the technical and human sides of modern healthcare.

For more information, visit the company website at https://lixte.com.

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

• ETST operates as an active strategic holding company, acquiring and optimizing businesses through direct management and governance.
• The company’s core operations focus on the health and wellness sector via a vertically integrated portfolio.
• ETST’s mission centers on building durable shareholder value through regulatory discipline, operational control, and scalable growth platforms.

A Hands-On Approach to Portfolio Management

Earth Science Tech (OTC: ETST) is redefining the traditional holding company model by building a diversified portfolio designed for long-term sustainability. Unlike passive investment vehicles, ETST takes an active role in its subsidiaries, utilizing hands-on management and disciplined execution to enhance performance across the board.

Through its wholly owned subsidiaries, ETST operates a vertically integrated network that includes high-quality compounding pharmacies, telemedicine platforms, and specialized healthcare facilities. This “driver’s seat” approach allows the company to dictate strategy, streamline capital allocation, and ensure rigorous regulatory compliance-critical factors in today’s complex healthcare landscape.

Capitalizing on the Digital Healthcare Revolution

ETST’s primary operations are positioned at the intersection of telemedicine and pharmaceutical service sectors experiencing a surge in demand driven by digital transformation and an aging population.

As the global healthcare market shifts toward tech-powered, cost-efficient delivery, ETST’s telemedicine platforms are uniquely positioned to scale. By focusing on businesses that can navigate complex regulatory environments, the company ensures that its growth is not just rapid, but resilient.

Diversification and Operational Excellence

Beyond healthcare, ETST’s portfolio extends into strategic real estate and consumer-focused markets. This multi-faceted approach provides a dual benefit:

• Balance Sheet Stability: Real estate holdings provide asset-backed value and financial grounding.
• Margin Expansion: Consumer-centric ventures offer high growth potential when paired with ETST’s centralized management and branding strategies.

The Path Forward: Methodical Growth

The firm’s acquisition philosophy targets businesses with clear operational improvement and sustainable revenue. By prioritizing practical, methodical growth over speculative expansion, the company mitigates risk while positioning its subsidiaries for measurable impact.

Through centralized oversight and standardized governance, Earth Science Tech is building a resilient platform capable of navigating market cycles and capturing emerging opportunities in essential industries.

For more information, visit EarthScienceTech.com.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST

• HeartBeam was included in a report published by Modern Healthcare that highlighted companies that achieved meaningful regulatory milestones or demonstrated forward momentum.
• HeartBeam’s technology is aligned with evolving regulatory and clinical priorities.
• In addition to being listed in the Modern Healthcare report, the company was also included in PatentVest’s “Total Cardiac Intelligence” report.

HeartBeam (NASDAQ: BEAT) was recently recognized among a select group of medical device companies featured in a January industry roundup highlighting recent U.S. Food and Drug Administration (“FDA”) clearances and approvals across the sector. The recognition underscores HeartBeam’s progress as it advances a novel approach to cardiac diagnostics through its HeartBeam System, a cable-free, high-fidelity ECG platform designed to capture the heart’s electrical signals from three distinct directions and synthesize them into a 12-lead ECG for arrhythmia assessment.

The company was included in a report published by Modern Healthcare and authored by Lauren Dubinsky. The report examined recent FDA activity across the medical device landscape, highlighting companies that achieved meaningful regulatory milestones or demonstrated forward momentum entering the new year. HeartBeam was included as part of this broader discussion of innovation and regulatory progress within the sector, reflecting growing attention on technologies aimed at improving access to clinical-grade data outside of traditional healthcare settings.

Being cited in the Modern Healthcare report places HeartBeam alongside other device developers whose products have either secured regulatory clearance or are progressing through the FDA process. The roundup focused on how recent approvals and regulatory decisions may shape the medical device market in the year ahead, particularly as healthcare systems continue to adopt technologies that support decentralization, remote monitoring and earlier intervention. HeartBeam’s mention reflects the relevance of its approach within these broader industry trends.

HeartBeam’s technology is aligned with evolving regulatory and clinical priorities. While many portable cardiac monitoring devices on the market provide limited, single-lead data intended primarily for wellness or screening purposes, HeartBeam is focused on delivering higher-fidelity signals. This emphasis on clinical-grade data helps explain why the company was included in a report centered on FDA activity and medical device innovation, rather than consumer health technology alone.

In addition to being listed in the Modern Healthcare report, the company was also included in PatentVest’s “Total Cardiac Intelligence” report. “HeartBeam recently reinforced its technology leadership with recognition as a Global IP and Technology Leader in Portable Cardiac Diagnostics, ranking second worldwide and trailing only GE Healthcare, in 12-lead ECG innovation among 243 companies evaluated,” the company noted in the announcement. The ranking reflects the strength of [HeartBeam’s] intellectual-property foundation, with 82 global patent publications across 15 patent families supporting its three-dimensional cardiac signal capture and 12-lead ECG synthesis architecture, underscoring the company’s growing influence in next-generation remote cardiac monitoring.

Beyond this recognition, the company continues to build toward its longer-term objective of bringing clinical-grade cardiac insights into more accessible environments. HeartBeam’s core platform, the HeartBeam System, is designed as the first cable-free, high-fidelity ECG system capable of capturing electrical signals from three distinct directions. This multidirectional approach enables a more comprehensive view of cardiac electrical activity than is possible with traditional handheld or wearable ECG devices that rely on a single signal pathway.

The HeartBeam System integrates electrodes into a compact handheld form factor, allowing patients to record ECG signals without adhesive patches, wires or external sensors. By simplifying the recording process while maintaining signal quality, the system is intended to support use in nonclinical settings, including at home or during symptomatic episodes that might otherwise go undocumented.

The inclusion of HeartBeam in the Modern Healthcare FDA roundup also highlights the growing importance of regulatory engagement for emerging medical device companies. Navigating the FDA process is a critical step in translating innovative technology into tools that can be adopted within mainstream healthcare. HeartBeam is working closely with regulators as it advances its platform, positioning the company to participate in a healthcare environment that increasingly values validated, high-quality data delivered beyond traditional care settings.

As the medical device sector enters the new year, attention is increasingly focused on technologies that can expand access to care, improve diagnostic efficiency and support earlier intervention. HeartBeam’s appearance in an industry-wide review of FDA activity reflects its alignment with these priorities. By developing a portable, cable-free ECG system designed to deliver clinically meaningful insights, the company is aiming to address persistent gaps in cardiac monitoring and arrhythmia assessment.

For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

Disseminated on behalf of  Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising.

• Powermax released Phase 2 stream sediment assay results from its Cameron Rare Earth Element Project in British Columbia, showing elevated light, heavy, and total rare earth oxides, across multiple drainage catchments.
• Results point to potential upstream bedrock sources and define priority areas for follow-up exploration.
• The company plans to integrate these findings with pending soil and rock sample data.
• Powermax is advancing a portfolio of REE assets in Canada and the U.S., including projects in Ontario and Wyoming.

Powermax Minerals (CSE: PMAX) (OTCQB: PWMXF), a Canadian mineral exploration company, recently reported new assay results from its Phase 2 stream sediment sampling program at the Cameron Rare Earth Element (“REE”) Project in British Columbia, outlining a series of anomalous rare earth values that management says will help refine exploration targets (https://ibn.fm/Ogebu).

The Toronto-based company said sampling across multiple drainage systems returned elevated light rare earth oxides (“LREO”), heavy rare earth oxides (“HREO”), and total rare earth oxides (“TREO”), reinforcing the effectiveness of stream sediment geochemistry as a tool for identifying REE mineralization. According to Powermax, Phase 2 assay results showed:

• LREO values ranging from 178.6 parts per million (“ppm”) to 47,980.5 ppm
• HREO values from 49.0 ppm to 9,537.3 ppm
• TREO values from 227.7 ppm to 57,517.8 ppm

Several drainage catchments displayed coherent multi-element anomalies, with enrichment in both light and heavy rare earths. The company also reported consistently high eTh/K ratios (greater than 10 in many samples), suggesting the presence of thorium-rich accessory minerals such as monazite or xenotime being transported downstream.

Management said these patterns indicate likely upstream bedrock sources and help define priority zones for follow-up geological mapping, soil sampling, and potential trenching or drill testing, subject to permitting.

“The Phase 2 stream sediment assay results further validate our systematic exploration approach at the Cameron Rare Earth Element Project,” CEO Paul Gorman said. “The broad range of elevated LREO, HREO, and TREO values across multiple drainage catchments highlights the extent and consistency of REE anomalies and confirms stream sediment geochemistry as an effective tool for defining priority target areas.” Gorman added that the company will integrate the new data with soil and rock sample results that are currently being processed.

Sampling for the Phase 2 program focused on active drainage systems. Sediments were sieved to less than 18 mesh and analyzed by AGAT Laboratories in Calgary, an ISO/IEC 17025:2017 accredited facility, using its 201-380 metals package. Powermax said quality control included the insertion of field duplicates. The Cameron REE Project is located in the Kamloops Mining Division of British Columbia and comprises three mineral claims totaling roughly 2,984 hectares. Powermax holds an option to acquire the property.

Beyond Cameron, Powermax is building a broader REE-focused portfolio. The company also holds options on the Atikokan REE Property and the Pinard REE Property in northern Ontario and owns a 100% interest in the Ogden Bear Lodge Project in Crook County, Wyoming.

Powermax positions itself as an early-stage exploration company aiming to identify and define economically viable rare earth deposits in Canada and the United States.

The company’s latest results arrive as rare earth elements continue to draw attention from investors and policymakers alike. Global demand for REEs is projected to rise sharply over the next decade, driven largely by electric vehicle production, wind power deployment, and other clean energy technologies. At the same time, China maintains a dominant role in both mining and processing, prompting efforts in North America to diversify supply chains.

In the United States, federal initiatives such as the Defense Production Act are being used to direct funding toward domestic and allied REE development, including grants and long-term purchase commitments. Canadian companies are eligible for parts of this funding, potentially providing additional support for exploration and downstream processing projects.

For Powermax, the Cameron results represent another technical data point as it works to advance its properties from early-stage exploration toward defined drill targets. While the company remains in the exploration phase, the growing dataset at Cameron is helping narrow the search for potential REE-bearing source rocks.

Exploration Target Cautionary Statement

The exploration targets discussed are conceptual, and there is currently not enough data to confirm a mineral resource. Further exploration may not yield successful results.

For more information, visit the company’s website at www.PowermaxMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to PWMXF are available in the company’s newsroom at https://ibn.fm/PWMXF

Disseminated on behalf of  ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising.

• ESGold Corp., a development-stage mining company, just added 144 new mining claims in and around its Montauban project in Quebec
• The expansion follows the recent completion of an ANT-based 3D geological model, suggesting the potential for a mineralized corridor extending approximately 900 meters in depth and over two kilometers of strike
• The expansion allows ESGold to systematically and strategically evaluate the full extent of the Montauban mineral system, marking a critical inflection point for the company, with evaluation that is no longer constrained by historical evaluations

ESGold (CSE: ESAU) (OTCQB: ESAUF), a development-stage company committed to acquiring, exploring, and developing high-quality mineral properties worldwide, just added 144 new mining claims in and around its Montauban project, bringing the total to 417 mining claims. This milestone represents the largest contiguous mineral tenure held by a single company in the region. The move also ensures that the company is not constrained by historical boundaries that previously limited its operations (https://ibn.fm/bXFk9).

The expansion follows the recent completion of an ambient noise tomography (“ANT”)- based 3D geological model, which suggested the potential for a mineralized corridor extending to approximately 900 meters in depth and over 2 kilometers of strike, remaining open beyond the limits of the existing survey area at the property.

“The recently completed 3D geological model fundamentally changed our understanding of Montauban and underscored the importance of securing control over the broader geological system,” noted Gordon Robb, ESGold’s CEO. “While we remain hyper-focused on advancing Montauban toward near-term production of our tailings project, we are moving exploration forward in tandem, recognizing the opportunity to create value on two tracks simultaneously,” he added (https://ibn.fm/bXFk9).

This development positions ESGold to systematically and strategically evaluate the full extent of the Montauban mineral system, particularly given modern exploration that has advanced beyond the historically mined footprint. Going forward, the company expects to significantly expand its ANT survey to cover approximately 70 square kilometers. The goal with this would be to assess the scale and continuity of the broader mineralized corridor.

“The addition of nearly 76 square kilometers of strategically positioned ground around Montauban is aimed at providing the scale necessary to properly evaluate the potential extent of the mineralized corridor identified by the model and to ensure we are not constrained by the historical boundaries as we systematically assess what Montauban may ultimately become,” Robb noted (https://ibn.fm/bXFk9).

ESGold also plans to integrate ANT results with existing geological, geochemical, and structural datasets for the property, along with developing a targeted step-out diamond-drilling program focused on testing high-priority targets identified by the model and expanded geophysics.

The expanded land position marks a critical inflection point for ESGold. The company is positioned to systematically evaluate the full potential of the emerging mineral system while not being constrained by its historical land base and boundaries. It is an opportunity for ESGold to redefine the scale of its historic mining camp, all while advancing towards production.

For company information, visit the company’s website at www.ESGold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF

• The BayesShield AI system analyzed a full year of real retail trading data to validate the company’s machine learning models.
• BayesShield is designed to predict loss probability at the individual trade level and intervene before execution and is being trained on more than 11.7 billion historical trades using NVIDIA hardware.
• Perpetuals operates regulated derivatives infrastructure rather than a balance-sheet exchange, avoiding custody and counterparty exposure by design, and plans to deploy BayesShield across its regulated trading venues, including a CySEC-authorized MiFID II MTF.

Perpetuals.com (NASDAQ: PDC), a fintech company focused on AI-driven digital asset trading solutions and regulated market infrastructure, announced that it has completed a pilot of its BayesShield(TM) artificial intelligence system, indicating that the technology would have successfully filtered out 92% of losing retail trades in Bitcoin perpetual futures based on a year-long backtest of real trading activity (https://ibn.fm/Vbl3F).

The company reported that the BayesShield AI Pilot Program analyzed historical BTC-USD perpetual futures trades and identified patterns that predicted losses before execution. Chief Executive Patrick Gruhn said the findings validate years of research into retail trading behavior. “The data show that the vast majority of retail losses in leveraged derivatives markets are predictable and preventable,” Gruhn said in the statement. He added that BayesShield is intended to change how trading platforms manage retail risk by identifying high-probability losing trades before they reach the market.

The pilot comes amid volatile cryptocurrency conditions that have tested retail traders with sharp price swings. Perpetuals said BayesShield’s predictive models are designed to operate in real time, calculating win-loss probabilities using both individual trader profiles and aggregated market sentiment.

Perpetuals said it has begun full-scale development of BayesShield following the pilot. The production system is being trained on NVIDIA hardware using one of the largest retail trading datasets the company has assembled. That dataset includes more than 11.7 billion individual trades across multiple years, over one million unique user histories, cryptocurrency spot markets such as Bitcoin and Ethereum, crypto derivatives including perpetual futures and options, and selected traditional equity markets to support cross-asset validation.

According to the company, BayesShield is designed not only to protect retail participants but also to help product issuers, such as derivatives platforms and market makers, optimize hedging strategies by understanding loss probabilities before trades are executed.

Perpetuals said the system analyzes profit-and-loss profiles at the individual level while also modeling broader behavioral patterns across the market. “The retail derivatives market has historically operated on a model where the majority of participants lose money,” Gruhn said. “By predicting which trades are likely to fail before they execute, we can create trading environments that are both more ethical and more sustainable for all participants.”

Perpetuals has announced that BayesShield will be deployed across its regulated trading infrastructure, including a third-party, CySEC-authorized MiFID II MTF. A broader commercial rollout is planned for the second half of the year, with institutional partners and trading platforms invited to begin integration discussions.

Perpetuals.com operates as a regulated digital market infrastructure provider rather than a traditional exchange. The company offers an API-driven platform that enables brokers, institutions, and trading venues to access crypto and tokenized derivatives within compliant frameworks.

Unlike many offshore crypto venues, Perpetuals is structured to avoid custody of client assets and balance-sheet exposure, positioning itself as infrastructure rather than a trading counterparty. The platform is built around an EU Multilateral Trading Facility (“MTF”) framework and is designed to support crypto spot trading, perpetual futures, options, swaps, and tokenized structured products.

The company says this model addresses a structural gap in Europe, where regulatory constraints limit how brokers can offer leveraged crypto products, even as retail demand continues to grow. By providing regulated knock-out instruments and structured products, Perpetuals aims to offer leveraged exposure while remaining within European regulatory limits.

The company operates at the intersection of crypto derivatives, CFD brokerage infrastructure, and tokenized financial products. Industry data cited by Perpetuals show the global crypto perpetual futures market processing roughly $2.18 trillion in monthly volume, while Europe’s CFD market generates approximately $17.34 trillion in monthly notional volume.

European regulators restrict CFD brokers from offering high-leverage crypto products, creating a gap between trader demand and compliant access. Perpetuals is targeting that gap by providing regulated infrastructure that supports leveraged exposure without relying on offshore venues.

For more information, visit the company’s website at https://group.perpetuals.com.

NOTE TO INVESTORS: The latest news and updates relating to PDC are available in the company’s newsroom at https://ibn.fm/PDC

• One of the key advantages of photodynamic therapy is its selectivity.
• Soligenix is advancing HyBryte(TM), or SGX301, designed for the treatment of cutaneous T-cell lymphoma.
• The company has achieved an important safety milestone in its confirmatory phase 3 clinical trial of HyBryte for CTCL treatment.

From lab research to clinical application, photodynamic therapy (“PDT”) is emerging as a powerful treatment approach that uses light and chemistry to selectively target diseased tissue. As this modality gains attention for its precision and safety profile, Soligenix (NASDAQ: SNGX) is developing light-activated therapies designed to treat cutaneous T-cell lymphoma (“CTCL”) and other inflammatory skin diseases using targeted photodynamic mechanisms that aim to improve outcomes while minimizing systemic toxicity.

“Cancer therapy, especially for tumors near sensitive areas, demands precise treatment,” states a Frontier report on PDT, a treatment method leveraging photosensitizers (“PS”), specific wavelength light and oxygen to target cancer effectively. “Recent advancements affirm PDT’s efficacy, utilizing ROS generation to induce cancer cell death. With a history spanning over decades, PDT’s dynamic evolution has expanded its application across dermatology, oncology and dentistry.”

PDT is a treatment technique that combines a photosensitizing drug with a specific wavelength of light to produce reactive oxygen species that selectively destroy abnormal cells. According to the National Cancer Institute (“NCI”), PDT works by administering a photosensitizer that accumulates in cancer or diseased tissue and then activating it with light, causing a localized reaction that damages targeted cells while largely sparing surrounding healthy structures. This targeted approach distinguishes PDT from traditional systemic treatments such as chemotherapy, which circulate throughout the body and can produce widespread side effects.

One of the key advantages of photodynamic therapy is its selectivity. Because the therapy is activated only where light is applied, clinicians can limit damage to nearby healthy tissue, potentially reducing long-term toxicity compared with radiation or cytotoxic drugs. “When cells that have absorbed photosensitizers are exposed to a specific wavelength of light, the photosensitizer produces a form of oxygen, called an oxygen radical, that kills them,” explains NCI. “Photodynamic therapy may also damage blood vessels in the tumor, which prevents it from receiving the blood it needs to keep growing. And, it may trigger the immune system to attack tumor cells, even in other areas of the body.”

Despite these advantages, traditional photodynamic approaches have faced limitations related to photosensitizer chemistry, depth of light penetration and treatment protocols. Advances in drug design and light delivery systems are now helping overcome these challenges. Researchers are increasingly exploring photosensitizers that respond to visible light wavelengths rather than damaging ultraviolet radiation, which may offer safer activation profiles and improved tissue penetration. The development of more refined photodynamic platforms is expanding the potential clinical applications of this modality.

Within this evolving landscape, Soligenix is advancing HyBryte(TM), or SGX301, the company’s proprietary photodynamic therapy based on synthetic hypericin, designed for the treatment of early stage cutaneous T-cell lymphoma. CTCL is a rare form of non-Hodgkin lymphoma that primarily affects the skin and can significantly impact quality of life through persistent lesions, itching and chronic symptoms. According to the Cutaneous Lymphoma Foundation, CTCL often requires long-term management and treatment strategies that balance effectiveness with tolerability, particularly in early-stage disease. HyBryte aims to address this need by providing a targeted, nonsystemic therapy activated by safe visible light.

Unlike systemic treatments that circulate throughout the body, HyBryte involves topical application followed by controlled exposure to visible light, activating the drug locally in affected skin areas. HyBryte also leverages visible fluorescent or LED light activation rather than ultraviolet wavelengths, aligning with broader trends toward safer photodynamic strategies. This approach is designed to selectively destroy malignant cells while minimizing systemic exposure, potentially improving safety and tolerability compared with traditional therapies.

Soligenix has evaluated HyBryte in multiple clinical studies for CTCL, where photodynamic therapy offers a particularly appealing strategy due to the disease’s skin-focused nature. Late last year, the company achieved an important safety milestone in its confirmatory Phase 3 clinical trial of HyBryte for CTCL treatment. The company announced that its first Data Monitoring Committee meeting for its confirmatory Phase 3 study concluded that there are no safety concerns with the ongoing Phase 3 study and that HyBryte has an acceptable safety profile that remains consistent with the safety data from all prior clinical studies. 

Clinical development efforts have focused on demonstrating efficacy while maintaining quality of life, an important consideration given the chronic nature of CTCL and the potential side effects associated with systemic therapies such as chemotherapy or immunomodulators. The localized activation mechanism of photodynamic therapy allows repeated treatments with potentially fewer cumulative toxicities, making it an attractive alternative for long-term disease management.

Beyond oncology, Soligenix is also exploring the potential of HyBryte in psoriasis, a chronic inflammatory skin disease affecting millions worldwide. The expansion into additional dermatologic indications highlights the flexibility of photodynamic platforms, which can be adapted to target different pathological processes depending on the photosensitizer used and the treatment protocol. As research continues, photodynamic therapy may evolve into a versatile platform capable of addressing both malignant and nonmalignant inflammatory skin conditions.

The broader promise of photodynamic therapy lies in its ability to bridge precision medicine and targeted drug delivery. Rather than relying solely on molecular targeting or systemic exposure, PDT introduces a physical activation step through light, enabling clinicians to control where and when treatment occurs. As researchers refine photosensitizers and light delivery technologies, the therapy’s potential applications could expand further into deeper tumors, combination regimens and immune-modulating strategies.

Companies such as Soligenix are contributing to this exploration by advancing therapies that combine selective targeting with improved safety profiles, offering hope for patients who need effective options with fewer systemic burdens. From the laboratory to clinical practice, the continued development of light-activated therapies underscores the growing role of precision-focused approaches in the future of disease treatment.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• Perpetuals.com focuses on 24/7, self-clearing trading venues that remove reliance on traditional clearing houses, representing an ethical alternative to questionable offshore exchanges and prediction markets.
• Proprietary machine learning tools are used to analyze risk and profit-and-loss probabilities at the trade level, with a dependable platform designed to comply with MiFID II and MiCA regulatory frameworks.
• The company’s Ledgera platform enables low-cost, cross-chain settlement with quantum-resilient security.

Perpetuals.com (NASDAQ: PDC), a fintech company focused on AI-driven digital asset trading solutions and regulated market infrastructure, is positioning itself at the intersection of traditional financial infrastructure and blockchain-based systems, targeting institutions that want exposure to digital assets without stepping outside regulated frameworks. The company develops software that allows regulated trading venues to operate continuously, with self-clearing and blockchain-native settlement replacing legacy post-trade processes.

Headquartered with operations across the United States, Europe, and Asia, Perpetuals.com is focused on financial market infrastructure rather than retail speculation. Its strategy reflects a broader shift among exchanges, brokers, and market operators that are seeking to modernize derivatives and crypto trading while remaining compliant with evolving regulatory regimes.

At the core of the company’s offering is infrastructure that removes the need for traditional clearing houses. By combining blockchain-based settlement with real-time risk assessment, Perpetuals aims to shorten settlement cycles and reduce counterparty exposure. The model is designed for markets that operate 24/7, a structural difference from legacy clearing systems built around limited trading hours.

Risk management plays a central role in this approach. Perpetuals uses proprietary machine learning models to analyze profit-and-loss probabilities at the individual trade level. According to the company, this enables exchanges and trading venues to design products with clearer risk parameters and stronger client protection, while also optimizing margining and capital efficiency.

The company’s technology stack is paired with blockchain infrastructure originally developed at EarlyWorks, the predecessor company whose assets were integrated into Perpetuals. EarlyWorks applied blockchain technology across a range of commercial use cases, including advertising verification, visitor management, and non-fungible token sales. Within Perpetuals, that blockchain experience has been repurposed for financial market settlement and custody.

One of the company’s flagship offerings is an AI-driven derivatives trading platform intended to modernize how derivatives are listed, traded, and settled. Rather than focusing on speculative leverage, the platform emphasizes transparency, continuous risk evaluation, and regulatory alignment. The company states that its systems are designed to comply with both MiFID II in Europe and the Markets in Crypto-Assets (“MiCA”) framework, which is shaping how digital asset services operate across the EU.

Beyond trading venues, Perpetuals has expanded into digital asset custody with its Quantum-Resilient Crypto Vaults, branded as Perpetuals.com Vaults. These vaults are designed as a self-custody solution for institutions that want to avoid reliance on third-party custodians or physical hardware wallets. The system combines infrastructure-level security with quantum-resilient cryptography, offering an alternative to audit-heavy or custodial models that introduce counterparty risk.

Management positions Perpetuals as an ethical alternative to offshore exchanges and prediction markets that operate outside regulatory oversight, for institutions and professional users that require legal certainty, predictable governance, and infrastructure that can integrate with existing financial systems.

This positioning reflects the backgrounds of the company’s leadership. Perpetuals was launched by executives with experience in European digital asset trading and market infrastructure, where regulatory scrutiny has been higher than in many offshore jurisdictions. That experience appears to inform the company’s emphasis on compliance-first design rather than retrofitting controls after the fact.

A practical illustration of this philosophy is Ledgera, a platform the company describes as a “meta blockchain” designed to sit above multiple Layer-1 networks. Ledgera functions as a Layer-2 settlement and abstraction layer, enabling transactions and asset movements across different blockchains without requiring users to interact directly with each underlying chain.

Ledgera is designed to combine quantum-resilient security with cross-chain interoperability. By abstracting Layer-1 complexity into a unified settlement engine, the platform aims to deliver high-speed transactions while maintaining sovereignty over assets. The company says this approach can reduce costs significantly compared with executing transactions directly on Layer-1 blockchains, where fees and congestion remain persistent challenges.

For institutional users, the appeal lies in unified control and cross-chain settlement without sacrificing compliance. Ledgera is intended to validate and coordinate activity across independent blockchains, allowing firms to settle trades, manage liquidity, or build fintech products without locking themselves into a single network. The company frames this as infrastructure that supports scale rather than experimentation.

Patrick Gruhn, CEO and founder of Perpetuals.com, has described Ledgera as an attempt to address what he sees as a structural tension in digital assets. “We designed Ledgera to solve the fundamental tension in digital assets: the tradeoff between speed and security, between decentralization and compliance. By abstracting Layer-1 complexity into a unified settlement engine, we’ve created infrastructure that’s fast enough for institutional trading, secure enough for self-custody, and flexible enough to span every chain that matters,” Gruhn said.

For more information, visit the company’s website at https://group.perpetuals.com.